Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CEFTAZIDIME Cause Intentional product use issue? 9 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Intentional product use issue have been filed in association with CEFTAZIDIME (TAZICEF). This represents 0.3% of all adverse event reports for CEFTAZIDIME.

9
Reports of Intentional product use issue with CEFTAZIDIME
0.3%
of all CEFTAZIDIME reports
0
Deaths
1
Hospitalizations

How Dangerous Is Intentional product use issue From CEFTAZIDIME?

Of the 9 reports, 1 (11.1%) required hospitalization, and 2 (22.2%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CEFTAZIDIME. However, 9 reports have been filed with the FAERS database.

What Other Side Effects Does CEFTAZIDIME Cause?

Drug ineffective (518) Off label use (266) Condition aggravated (228) Septic shock (200) Acute kidney injury (191) Pyrexia (176) Endophthalmitis (128) Multiple organ dysfunction syndrome (124) Neutropenia (123) Drug reaction with eosinophilia and systemic symptoms (121)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which CEFTAZIDIME Alternatives Have Lower Intentional product use issue Risk?

CEFTAZIDIME vs CEFTIBUTEN CEFTAZIDIME vs CEFTOLOZANE\TAZOBACTAM CEFTAZIDIME vs CEFTRIAXONE CEFTAZIDIME vs CEFTRIAXONE\CEFTRIAXONE CEFTAZIDIME vs CEFUROXIME

Related Pages

CEFTAZIDIME Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue CEFTAZIDIME Demographics